PRESS RELEASESCATCH UP WITH OUR LATEST PRESS RELEASES April 28, 2025Capsida to Present Progress Updates at the ASGCT Annual Meeting, Including NHP GLP Toxicology Study Results for its Potential First-in-Class STXBP1 Developmental and Epileptic Encephalopathy Program (CAP-002 STXBP1-DEE) April 3, 2025Capsida Presents New Data from GLP Toxicology Study in NHPs Demonstrating Potential Best-in-Class Profile of CAP-003 in Patients with Parkinson’s Disease Associated with GBA Mutations (PD-GBA) January 7, 2025Capsida Announces AbbVie Opt-in for First Genetic Medicine Program from Neurodegenerative Disease Collaboration December 19, 2024Capsida Biotherapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference December 6, 2024New Preclinical Data Demonstrate Potential of Capsida’s IV Gene Therapy for STXBP1-DEE to Correct all Disease Manifestations November 25, 2024Capsida Biotherapeutics to Present at 7th Annual Evercore HealthCONx Conference November 12, 2024Capsida Biotherapeutics to Present New Preclinical Data for Potential Best-in-Class Friedreich’s Ataxia Next-Generation Gene Therapy October 30, 2024FDA Grants Orphan Drug Designation to Capsida Biotherapeutics for Potential Treatment of STXBP1 Developmental and Epileptic Encephalopathy October 7, 2024New Data Demonstrate Substantial Therapeutic Potential of Capsida’s IV Gene Therapy for Parkinson’s Disease Associated with GBA Mutations September 4, 2024Capsida Biotherapeutics to Participate in Upcoming Investor and Industry Conferences Highlighting Progress With its Wholly Owned Programs in IND-enabling Studies May 10, 2024Capsida Biotherapeutics to Present Preclinical Data for Parkinson’s Disease Associated with GBA Mutations Showing High Levels of GCase Enzyme Supplementation Following IV Administration May 7, 2024Capsida Biotherapeutics Presents New Preclinical Evidence Indicating Novel First-in-Class IV-Administered Gene Therapy Effectively Treats Genetic Epilepsy Due to STXBP1 Mutations April 22, 2024Capsida Biotherapeutics to Present New Data on its Wholly Owned Gene Therapy Programs in Genetic Epilepsy and Parkinson’s Disease at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) March 12, 2024Capsida Biotherapeutics Announces Promotion of Rob Murphy to Chief Manufacturing and Quality Officer February 21, 2024Capsida Biotherapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference October 3, 2023Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx’s Next-Generation Gene Therapies September 20, 2023Capsida Biotherapeutics to Present at Jefferies Cell & Genetic Medicine Summit and the 2023 Cell & Gene Meeting on the Mesa July 11, 2023Capsida Biotherapeutics Announces Publication in Nature Nanotechnology Identifying Novel Capsid With Significantly Increased Brain Transduction June 2, 2023Capsida Biotherapeutics to Present New Preclinical Data on Potential of Systemically Delivered Next-Generation AAV Therapeutics for Treatment of Genetic Epilepsy May 10, 2023Capsida Biotherapeutics to Present New Data Showing Increased Capsid Expression in CNS at American Society of Gene & Cell Therapy 26th Annual Meeting March 7, 2023Capsida Biotherapeutics Appoints Susan Catalano, Ph.D. as Chief Scientific Officer February 23, 2023AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need January 18, 2023Capsida Biotherapeutics Announces Appointment of Julie Hakim as Chief Financial Officer January 4, 2023Capsida Biotherapeutics Announces Strategic Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Develop Non-Invasive Gene Therapies for CNS Diseases May 18, 2022Capsida Biotherapeutics Presents Data Demonstrating Unique Industry-Leading Technology and Capabilities With Potential to Treat Both Rare and Common Diseases at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) May 17, 2022Capsida Biotherapeutics Presents New Data Validating Potential of Its Targeted, Non-invasive Gene Therapy Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) April 19, 2022Capsida Co-Founders Named to Endpoints’ Top 20 Scientists Under 40 March 22, 2022Capsida Biotherapeutics Announces Appointment of Rayne Waller to Chief Operating Officer February 3, 2022PharmaVoice profiles Capsida CEO Peter Anastasiou December 9, 2021Capsida Biotherapeutics Announces Publication in Nature Neuroscience From Caltech Demonstrating Robust, Non-invasive IV Gene Delivery Targeted to the Brain While Avoiding Liver December 7, 2021Capsida Biotherapeutics Poised to Capitalize on Industry-leading Gene Therapy Technology With New CEO, CSO, and CTO December 2, 2021Capsida Technology and Clinical Leadership to Present at Gene Therapy for Neurological Disorders Conference July 22, 2021Capsida Biotherapeutics Unveils Next-Generation Gene Therapy Manufacturing June 15, 2021CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia May 12, 2021Capsida Appoints Swati Tole, M.D., as Chief Medical Officer April 29, 2021Capsida Biotherapeutics Debuts with $140 Million of Capital
